|Bid||0.00 x 2200|
|Ask||0.00 x 1800|
|Day's range||8.22 - 8.51|
|52-week range||7.73 - 13.30|
|Beta (5Y monthly)||1.30|
|PE ratio (TTM)||12.47|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||27 Nov 2017|
|1y target est||11.36|
Berkshire Hathaway CEO Warren Buffett is one of the most successful value investors of all time. Although classic value stocks fell out of favor during the nearly decade-long bull market over the course of 2010 to 2020, and Berkshire's stock underperformed some major U.S. stock indexes as a result, these tried and true investing vehicles are making a furious comeback during this current bear market. The long and short of it is that the increasing likelihood of rising interest rates and stubbornly high levels of inflation ought to favor Buffett's value-oriented approach to investing over narrative-driven growth stocks in 2022.
If we strictly looked at the performance of the major U.S. stock indexes, 2021 was a great year. While no investor enjoys seeing their stocks go in reverse, patience has a way of paying off handsomely in the stock market. In 2022, the following trio of turnaround stocks have the catalysts needed to bounce back in a big way.
TEL AVIV, Israel, January 18, 2022--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2021 financial results, as well as on its financial guidance for 2022, on Wednesday, February 9, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.